Skip to main content

Table 1 Patient demographics and clinical characteristics

From: The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma

Demographics or clinical characteristics Cis/carboplatin and pemetrexed (n = 116) Cis/carboplatin and gemcitabine (n = 30) p value
Mean age, years 60.7 ± 10.9 60.8 ± 9.9 0.945
Male: Female 58 : 58 14 : 16 0.745
Asbestos exposure, n (%) 113 (97.4) 29 (96.7) 0.827
Mean Karnofsky Performance Status 85.7 ± 9.9 80.3 ± 8.7 0.062
Histology, n (%)    
Epithelial 92 (79.3) 22 (73.3) 1.00
Sarcomatous 9 (7.8) 2 (6.7)
Mixed 12 (10.3) 5 (16.7)
Unidentified 3 (2.6) 1 (3.3)
Stage, n (%)    
I 6 (5.2) 2 (6.7) 0.662
II 12 (10.4) 2 (6.7)
III 41 (35.7) 14 (46.7)
IV 56 (48.7) 12 (40.0)
Pleurodesis, n (%) 41 (35.3) 10 (33.3) 0.837
Prophylactic radiotherapy, n (%) 22 (19.0) 2 (6.7) 0.083
Second–line chemotherapy, n (%) 36 (31.0) 8 (26.7) 0.642
Median baseline hemoglobin, g / dL 12.5 12.3 0.679
Median baseline serum albumin, g / dL 3.8 3.6 0.336